firocoxib has been researched along with dinoprostone in 7 studies
| Studies (firocoxib) | Trials (firocoxib) | Recent Studies (post-2010) (firocoxib) | Studies (dinoprostone) | Trials (dinoprostone) | Recent Studies (post-2010) (dinoprostone) |
|---|---|---|---|---|---|
| 102 | 43 | 71 | 29,105 | 1,346 | 6,357 |
| Protein | Taxonomy | firocoxib (IC50) | dinoprostone (IC50) |
|---|---|---|---|
| Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | 0.0155 | |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | 0.0031 | |
| Prostaglandin E2 receptor EP4 subtype | Rattus norvegicus (Norway rat) | 0.0021 | |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | 0.002 | |
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | 0.0087 | |
| Prostacyclin receptor | Homo sapiens (human) | 0.26 | |
| Prostaglandin E2 receptor EP2 subtype | Rattus norvegicus (Norway rat) | 0.0052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Budsberg, SC; Goodman, LA; Reynolds, LR; Torres, BT | 1 |
| Barton, MH; Budsberg, S; Giguère, S; King, D; Norton, N; Paske, E | 1 |
| Chandler, KJ; Sutton, DG | 1 |
| Barlow, BM; Blikslager, AT; Curling, A; Davis, JL; Fogle, C; Holland, B; Schirmer, J | 1 |
| Boos, A; Domosławska, A; Fingerhut, J; Gram, A; Hoffmann, B; Ihle, S; Janowski, T; Jurczak, A; Kowalewski, MP; Schuler, G; Siemieniuch, MJ; Zduńczyk, S | 1 |
| Barton, MH; Clifton, S; Darden, JE; Vandenplas, M | 1 |
| Beale, B; Jarudecha, T; Kashemsant, N; Kwananocha, I; Lascelles, BDX; Lekcharoensuk, C; Peirone, B; Vijarnsorn, M | 1 |
4 trial(s) available for firocoxib and dinoprostone
| Article | Year |
|---|---|
Efficacy of cyclo-oxygenase inhibition by two commercially available firocoxib products in horses.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dosage Forms; Horses; Sulfones | 2014 |
Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Dinoprostone; Horses; Injections, Intravenous; Ointments; Sulfones; Tablets; Thromboxane B2 | 2015 |
Formation of the early canine CL and the role of prostaglandin E2 (PGE2) in regulation of its function: an in vivo approach.
Topics: 4-Butyrolactone; Animals; Corpus Luteum; Dinoprost; Dinoprostone; Dogs; Female; Gene Expression Regulation; Intramolecular Oxidoreductases; Male; Prostaglandin-E Synthases; Receptors, Prostaglandin; Sulfones | 2015 |
The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dinoprostone; Dog Diseases; Dogs; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Unsaturated; Female; Gait; Male; Osteoarthritis; Pain; Pain Measurement; Prospective Studies; Sulfones | 2019 |
3 other study(ies) available for firocoxib and dinoprostone
| Article | Year |
|---|---|
Effects of firocoxib, meloxicam, and tepoxalin administration on eicosanoid production in target tissues of healthy cats.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cats; Cross-Over Studies; Cyclooxygenase Inhibitors; Dinoprostone; Duodenum; Eicosanoids; Gastric Mucosa; Intestinal Mucosa; Kinetics; Leukotriene B4; Male; Meloxicam; Orchiectomy; Pyrazoles; Reference Values; Sulfones; Thiazines; Thiazoles | 2010 |
The dilemmas of medicine selection for equine veterinarians.
Topics: 4-Butyrolactone; Animals; Cyclooxygenase 2 Inhibitors; Dinoprostone; Horses; Sulfones | 2014 |
Effect of firocoxib on cyclooxygenase 2, microsomal prostaglandin E2 synthase 1, and cytosolic phospholipase A2 gene expression in equine mononuclear cells.
Topics: 4-Butyrolactone; Animals; Centrifugation, Density Gradient; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytosol; Dinoprostone; Gene Expression Regulation; Horses; Intramolecular Oxidoreductases; Leukocytes, Mononuclear; Lipopolysaccharides; Membrane Proteins; Microsomes; Phospholipases A2; Polymerase Chain Reaction; Prostaglandin-E Synthases; Sulfones | 2015 |